title: Twin pregnancy and childbirth after reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation combined with imatinib mesylate for chronic myeloid leukaemia: case report and literature review.
abstract: The successful outcome of a pregnancy in a woman who had received reduced-intensity conditioning (RIC) allogeneic haematopoietic stem cell transplantation (allo-HSCT) for chronic myeloid leukaemia is reported; publications on recovery of ovarian function and pregnancy following myeloablative  conditioning (MAC) or RIC allo-HSCT for haematological disorders are reviewed. Research suggests that RIC allo-HSCT may facilitate ovarian recovery. Indeed, in the case study presented, the patient had a successful twin pregnancy and delivery, subsequent to treatment. After a 5-year follow-up,  the patient survives disease-free with a sustained molecular response; her children are both healthy, with no physical defects. These findings suggest that RIC allo-HSCT combined with short-term imatinib mesylate does not necessarily have profound effects on female fertility.
authors: Bone Marrow Transplantation Centre, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
authors: K-N
authors: KN
authors: Wu
authors: Y
authors: Y
authors: Luo
authors: L-Z
authors: LZ
authors: Liu
authors: Y-M
authors: YM
authors: Zhao
authors: Y-X
authors: YX
authors: Hu
authors: Y-M
authors: YM
authors: Tan
authors: X-Y
authors: XY
authors: Lai
authors: H
authors: H
authors: Huang
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005298:Fertility / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000601:surgery*; D036801:Parturition; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011247:Pregnancy; D011256:Pregnancy Outcome; D059285:Pregnancy, Twin; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D019172:Transplantation Conditioning
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate